Altavant Sciences Gmbh

Stephen A Wring

Magdalena Alonso-Galicia

Eric J Gaukel

Michelle Palacios

There is provided a daily dosage regimen for treating pulmonary arterial hypertension. The regimen takes the form of two discrete dosage forms. Each dosage form includes an amount of about 600 mg to about 800 mg of (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1'-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate. There is also another method for providing a daily dosage regimen. There is also provided several methods for treating pulmonary arterial hypertension. There is provided a method for reducing the level of serotonin biosynthesis by at least 50%. There is also provided a method for achieving an AUCof &#x2265;2530 ng&#xb7;hr/mL of (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1&#x2032;-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid. There is provided a method of achieving a &#x3e;50% reduction in urinary 5-HIAA.

Growing community of inventors

South Boston, VA, United States of America

Stephen A Wring